[Form 4] LeMaitre Vascular, Inc. Insider Trading Activity

Rhea-AI Filing Summary

LeMaitre Vascular director John James O'Connor reported changes in beneficial ownership on Form 4 relating to dividend equivalent rights that accrued on previously granted equity awards. The filing shows transactions dated 09/04/2025 recording a series of small accruals of dividend equivalent rights tied to restricted stock units and performance share unit awards granted on 12/12/2022, 12/8/2023 and 12/6/2024. Each dividend equivalent right is described as the economic equivalent of one share of the issuer's common stock. The filing was signed by Nathan Ulrich on 09/08/2025. The report indicates the form was filed by one reporting person who is a director of the issuer (LMAT).

Positive

• Transparent disclosure of dividend equivalent accruals tied to prior RSU and PSU awards
• Reporting person identified as a director and the filing lists specific grant dates for the underlying awards

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Routine accrual of dividend equivalents on prior equity awards for a director; no cash transactions or option exercises reported.

The Form 4 documents accrual entries for dividend equivalent rights that vest proportionately with underlying restricted stock units and performance share units granted on specific prior grant dates. These entries are administrative in nature, reflecting earned economic equivalents rather than open-market purchases or sales. The reporting person is identified as a director and the filing was singular (one reporting person). The signature block shows the filing was signed by Nathan Ulrich on 09/08/2025, consistent with standard Form 4 execution practices.

Securities Analyst

TL;DR: Non-cash accruals of dividend equivalent rights recorded; no change to cash position or debt reported.

The transactions dated 09/04/2025 list multiple fractional amounts of dividend equivalent rights tied to RSU and PSU awards from 12/12/2022, 12/08/2023 and 12/06/2024. Each right is stated as economically equivalent to one share of common stock and several fractional amounts were reported as acquired (A) with $0 price, indicating accrual rather than purchase. The filing does not disclose any exercised derivatives, sales, purchases, or changes in indebtedness. Materiality appears limited to award accrual accounting for the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Connor John James

(Last) (First) (Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON MA 01803

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Dividend Equivalent Rights	(1)	09/04/2025		A		0.4173		(1)	(1)	Common Stock	0.4173	$0	6.5156	D
Dividend Equivalent Rights	(2)	09/04/2025		A		0.4173		(2)	(2)	Common Stock	0.4173	$0	5.5269	D
Dividend Equivalent Rights	(3)	09/04/2025		A		0.7138		(3)	(3)	Common Stock	0.7138	$0	5.3975	D
Dividend Equivalent Rights	(4)	09/04/2025		A		0.8546		(4)	(4)	Common Stock	0.8546	$0	5.8691	D
Dividend Equivalent Rights	(5)	09/04/2025		A		0.8697		(5)	(5)	Common Stock	0.8697	$0	2.9094	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/12/2022 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

3. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

4. These dividend equivalent rights accrued on a Performance Share Unit (PSU) award granted on 12/8/2023 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

5. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/6/2024 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Nathan Ulrich	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did John James O'Connor report on the Form 4 for LMAT?

He reported accruals of dividend equivalent rights on 09/04/2025 related to prior RSU and PSU awards; each is the economic equivalent of one share.

Do the transactions on this Form 4 involve purchases or sales of stock?

No. The entries are recorded as accruals of dividend equivalent rights with a $0 price, not open-market purchases or sales.

Which grant dates produced the dividend equivalent rights reported?

The dividend equivalents accrued on awards granted on 12/12/2022, 12/08/2023, and 12/06/2024.

When were the transactions and when was the Form 4 signed?

Transactions are dated 09/04/2025 and the Form 4 bears a signature by Nathan Ulrich dated 09/08/2025.

Was the Form 4 filed by more than one reporting person?

No. The form indicates it was filed by one reporting person.